Eledon Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ELDN, updated each market day.
ELDN AI Sentiment
AI sees no strong directional signal for Eledon Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Sector
Exchange
Market Cap
$235,140,338
Cap Tier
Employees
33
Headquarters
IRVINE, CA
Listed Since
Sept. 17, 2014
Website
ELDN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ELDN Volatility
Eledon Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
